Total Funding
90
55
Total FundingSeries D raised
Growth Score
-6 pts
Heat Score
-28 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
15511
ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.
- Keith Rubin: Founder and CEO
Peter Goldstein: Executive DirectorPast Role: Biscayne Pharmaceuticals, Director of Operations
About the Company
ILiAD Biotechnologies (ILiAD) is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. ILiAD's lead candidate is BPZE1, a live-attenuated pertussis vaccine that has successfully completed a Phase 1 human clinical trial.
ILiAD Biotechnologies is a registered Delaware company
founded in 2012.
